Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) [0.03%]
奥希替尼减量与EGFR突变阳性一线转移性非小细胞肺癌患者的生存期关系 исследование
Adam Barsouk,Alec Heidlauf,Keshav Goel et al.
Adam Barsouk et al.
Introduction: Osimertinib has become standard of carein 1 LEGFR-mutated(mt)mNSCLC following the FLAURA trial.However, limited data are available on the effect of osimertinib dose-reductionon outcomes compared tofull-dose....
Immune-related disorders in patients with Thymic Epithelial Tumors: from pathogenesis to tailored interventions [0.03%]
胸腺上皮肿瘤患者的免疫相关性疾病：从发病机制到个体化治疗
Erica Pietroluongo,Giovannella Palmieri,Paolo Antonio Ascierto et al.
Erica Pietroluongo et al.
Background and objective: Thymic epithelial tumors (TETs) are rare malignancies often associated with immunological disorders (IDs), including autoimmune diseases and paraneoplastic syndromes. Myasthenia gravis (MG) is th...
Diagnostic performance of monarch robotic bronchoscopy with and without mobile cone-beam CT support [0.03%]
Monarch机器人支气管镜联合移动式锥形束CT的诊断性能评估
Jingjing Chen,Dakota McNierney,Joe G Zein et al.
Jingjing Chen et al.
Background: Robotic-assisted bronchoscopy (RAB) is limited by CT-to-body divergence. Cone-beam CT (CBCT) may enhance tool-to-lesion alignment and diagnostic yield (DY), but the benefit of integrating mobile CBCT (mCBCT) i...
Monireh Sadat Seyyedsalehi,Massimiliano Cani,Qian Wang et al.
Monireh Sadat Seyyedsalehi et al.
Lung cancer (LC) remains the leading cause of cancer-related mortality among women worldwide. Compared to men, LC in women presents distinct epidemiologic, biological, and clinical characteristics. A large proportion of LC cases in women oc...
Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer [0.03%]
EGFR突变型非小细胞肺癌患者术前ctDNA和病理静脉侵犯的预后价值评估
Yuya Murase,Hayato Koba,Hideharu Kimura et al.
Yuya Murase et al.
Introduction: Curative surgery followed by adjuvant osimertinib according to pathological stage (pStage) is standard for resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Never...
Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study [0.03%]
Ommaya池联合鞘内化疗及全脑放疗可改善EGFR突变型NSCLC患者脑膜转移的生存率：真实世界队列研究
Meifang Li,Haibo Wang,Wei Zhang et al.
Meifang Li et al.
Objective: This study aimed to evaluate the survival benefit of combined intrathecal treatment (IT) via Ommaya reservoir and whole-brain radiotherapy (WBRT) in EGFR-mutant non-small cell lung cancer (NSCLC) patients with ...
KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence [0.03%]
网络荟萃分析和真实世界证据下的KRAS突变型晚期非小细胞肺癌的疗效及临床结局
Xiaoyu Gang,Yige Sun,Junli Hao et al.
Xiaoyu Gang et al.
Background: KRAS is a common driver gene in non-small cell lung cancer (NSCLC). Owing to the absence of universally effective targeted agents and marked heterogeneity, optimal treatment selection for KRAS-mutant NSCLC rem...
FAM83A promotes the progression of lung squamous cell carcinoma by inducing the epithelial-mesenchymal transition and inhibiting apoptosis via ERK pathway [0.03%]
FAM83A通过诱导上皮间质转化并抑制ERK途径凋亡促进肺鳞状细胞癌的进展
Xiang Fei,Hao Wu,Mengxing Li et al.
Xiang Fei et al.
Background: The protein Family with Sequence Similarity 83, Member A (FAM83A) is associated with the advancement of various tumors. This study examines the biological function and fundamental processes of FAM83A in lung s...
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG) [0.03%]
尼替尼布作为恶性胸膜间皮瘤的序贯维持治疗：一项双盲随机II期临床试验（EORTC-08112-LCG）
Omar Abdel-Rahman,Paul Taylor,Mary O&#x;Brien et al.
Omar Abdel-Rahman et al.
Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using nintedanib monotherapy as switch maintenance in pati...
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer [0.03%]
小细胞肺癌和转化型非小细胞肺癌中的SEZ6表达及谱系可塑性
Jennifer A Marks,Kieran Sweeney,Andrew Elliott et al.
Jennifer A Marks et al.
Introduction: Small cell lung cancer (SCLC) and extrapulmonary neuroendocrine (NE) tumors are aggressive malignancies with limited treatment options. Seizure-related homolog 6 (SEZ6) is a potential therapeutic target, but...